BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mou L, Tian X, Zhou B, Zhan Y, Chen J, Lu Y, Deng J, Deng Y, Wu Z, Li Q, Song Y, Zhang H, Chen J, Tian K, Ni Y, Pu Z. Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials. Front Oncol 2021;11:752725. [PMID: 34707994 DOI: 10.3389/fonc.2021.752725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Pang K, Wang W, Qin J, Shi Z, Hao L, Ma Y, Xu H, Wu Z, Pan D, Chen Z, Han C. Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. MedComm 2022;3. [DOI: 10.1002/mco2.175] [Reference Citation Analysis]
2 Filippi L, Bagni O, Notarianni E, Saltarelli A, Ambrogi C, Schillaci O. PET/CT with (18)F-choline or (18)F-FDG in Hepatocellular Carcinoma Submitted to (90)Y-TARE: A Real-World Study. Biomedicines 2022;10. [PMID: 36428565 DOI: 10.3390/biomedicines10112996] [Reference Citation Analysis]
3 Salimi A, Lim JH, Jang JH, Lee JY. The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors. Sci Rep 2022;12:18825. [PMID: 36335233 DOI: 10.1038/s41598-022-22992-6] [Reference Citation Analysis]
4 Huang S, Chong S, Huang C, Hsu H, Pan K, Hung C, Wu T, Lee C, Hsieh C, Wang C, Chai P, Yu M. Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma. Biomedicines 2022;10:2277. [DOI: 10.3390/biomedicines10092277] [Reference Citation Analysis]
5 Du F, Sun H, Sun F, Yang S, Tan H, Li X, Chai Y, Jiang Q, Han D. Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs. Front Pharmacol 2022;13:924523. [DOI: 10.3389/fphar.2022.924523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yang C, Mai Z, Liu C, Yin S, Cai Y, Xia C. Natural Products in Preventing Tumor Drug Resistance and Related Signaling Pathways. Molecules 2022;27:3513. [PMID: 35684449 DOI: 10.3390/molecules27113513] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Matrone A, Gambale C, Prete A, Elisei R. Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine. Front Endocrinol 2022;13:864253. [DOI: 10.3389/fendo.2022.864253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Zheng H, Zheng WJ, Wang ZG, Tao YP, Huang ZP, Yang L, Ouyang L, Duan ZQ, Zhang YN, Chen BN, Xiang DM, Jin G, Fang L, Zhou F, Liang B. Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell-Mediated Antitumor Activity. Front Immunol 2022;13:845193. [PMID: 35154166 DOI: 10.3389/fimmu.2022.845193] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]